BESPONSA Injection 1 mg Special Investigation

Pfizer

Status: Completed

Conditions: Acute Lymphocytic Leukemia

Study type: Observational

Funder types: Industry

Identifiers

NCT05923112

NCT05923112 (Registry Identifier)

B1931024

Details and patient eligibility

About

The purpose of this study is to learn about the safety and effectiveness of BESPONSA. BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia.

Registration criteria for this study is all patients who starting BESPONSA in Japan from its launch to the market to April 30, 2020.

All patients in this study will receive BESPONSA according to the prescriptions.

Patients will be followed up as follow.

• 52 weeks for patients who did not have a HSCT (Hematopoietic Stem Cell Transplant) within 52 weeks after starting BESPONSA.
• Up to 52 weeks after a HSCT for patients who had a HSCT within 52 weeks after starting BESPONSA.

Enrollment: 421 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients prescribed BESPONSA

Exclusion criteria

• None

Trial design